company background image
JAZZ

Jazz Pharmaceuticals NasdaqGS:JAZZ Stock Report

Last Price

US$157.25

Market Cap

US$9.9b

7D

2.8%

1Y

30.8%

Updated

03 Dec, 2022

Data

Company Financials +
JAZZ fundamental analysis
Snowflake Score
Valuation5/6
Future Growth4/6
Past Performance0/6
Financial Health2/6
Dividends0/6

JAZZ Stock Overview

Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally.

Jazz Pharmaceuticals plc Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Jazz Pharmaceuticals
Historical stock prices
Current Share PriceUS$157.25
52 Week HighUS$169.98
52 Week LowUS$119.76
Beta0.74
1 Month Change8.45%
3 Month Change1.53%
1 Year Change30.76%
3 Year Change5.21%
5 Year Change13.15%
Change since IPO786.92%

Recent News & Updates

Recent updates

Jazz Pharmaceuticals (NASDAQ:JAZZ) Seems To Use Debt Quite Sensibly

Aug 10
Jazz Pharmaceuticals (NASDAQ:JAZZ) Seems To Use Debt Quite Sensibly

Jazz Pharmaceuticals (NASDAQ:JAZZ) Takes On Some Risk With Its Use Of Debt

May 12
Jazz Pharmaceuticals (NASDAQ:JAZZ) Takes On Some Risk With Its Use Of Debt

Is Jazz Pharmaceuticals (NASDAQ:JAZZ) Using Too Much Debt?

Oct 02
Is Jazz Pharmaceuticals (NASDAQ:JAZZ) Using Too Much Debt?

Shareholders May Be A Bit More Conservative With Jazz Pharmaceuticals plc's (NASDAQ:JAZZ) CEO Compensation For Now

Jul 23
Shareholders May Be A Bit More Conservative With Jazz Pharmaceuticals plc's (NASDAQ:JAZZ) CEO Compensation For Now

We Think Jazz Pharmaceuticals (NASDAQ:JAZZ) Can Manage Its Debt With Ease

May 27
We Think Jazz Pharmaceuticals (NASDAQ:JAZZ) Can Manage Its Debt With Ease

Bullish: Analysts Just Made A Substantial Upgrade To Their Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Forecasts

May 06
Bullish: Analysts Just Made A Substantial Upgrade To Their Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Forecasts

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Shares Could Be 44% Below Their Intrinsic Value Estimate

May 03
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Shares Could Be 44% Below Their Intrinsic Value Estimate

Patricia Carr Is The Vice President of Finance & Principal Accounting Officer of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) And They Just Sold 25% Of Their Shares

Mar 11
Patricia Carr Is The Vice President of Finance & Principal Accounting Officer of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) And They Just Sold 25% Of Their Shares

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Is Going Strong But Fundamentals Appear To Be Mixed : Is There A Clear Direction For The Stock?

Mar 02
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Is Going Strong But Fundamentals Appear To Be Mixed : Is There A Clear Direction For The Stock?

Shareholder Returns

JAZZUS PharmaceuticalsUS Market
7D2.8%2.4%1.5%
1Y30.8%15.5%-14.9%

Return vs Industry: JAZZ exceeded the US Pharmaceuticals industry which returned 15.5% over the past year.

Return vs Market: JAZZ exceeded the US Market which returned -14.9% over the past year.

Price Volatility

Is JAZZ's price volatile compared to industry and market?
JAZZ volatility
JAZZ Average Weekly Movement4.6%
Pharmaceuticals Industry Average Movement11.0%
Market Average Movement7.4%
10% most volatile stocks in US Market15.6%
10% least volatile stocks in US Market3.3%

Stable Share Price: JAZZ is less volatile than 75% of US stocks over the past 3 months, typically moving +/- 5% a week.

Volatility Over Time: JAZZ's weekly volatility (5%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
20033,200Bruce Cozaddhttps://www.jazzpharma.com

Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement disorders; and in oncology, including hematologic and solid tumors. Its lead marketed products include Xyrem, an oral solution for the treatment of cataplexy and excessive daytime sleepiness (EDS) in narcolepsy patients seven years of age and older; Sunosi for the treatment of EDS in patients with narcolepsy and obstructive sleep apnea; Erwinaze to treat acute lymphoblastic leukemia; Defitelio for the treatment of adult and pediatric patients with hepatic veno-occlusive disease; Vyxeos liposome for injection, a product for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia; and Zepzelca for the treatment of adult patients with metastatic small cell lung cancer.

Jazz Pharmaceuticals plc Fundamentals Summary

How do Jazz Pharmaceuticals's earnings and revenue compare to its market cap?
JAZZ fundamental statistics
Market CapUS$9.90b
Earnings (TTM)-US$18.69m
Revenue (TTM)US$3.58b

2.8x

P/S Ratio

-529.9x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
JAZZ income statement (TTM)
RevenueUS$3.58b
Cost of RevenueUS$231.67m
Gross ProfitUS$3.35b
Other ExpensesUS$3.37b
Earnings-US$18.69m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.30
Gross Margin93.54%
Net Profit Margin-0.52%
Debt/Equity Ratio208.6%

How did JAZZ perform over the long term?

See historical performance and comparison